Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could silkworm pupas be the key to fighting muscle loss in cancer survivors?

NCT ID NCT07554807

Symptom relief Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether silkworm pupa tablets can improve nutrition and reduce muscle loss (sarcopenia) in people who have completed cancer treatment. 480 participants will receive either the tablets or a placebo for 3 months. The main goal is to see if muscle strength and mass improve.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
silkworm pupa tablets
What this could lead to
If it works, this could offer a simple, natural supplement to help cancer survivors regain muscle strength and improve nutrition.
What could go wrong
This is an early-stage test of a supplement, not a proven treatment. The effect may be small or no better than placebo, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 480 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. fully understand and sign the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures 2. Any gender, age at ICF signing: ≥ 18 years, ≤ 80 years 3. Confirmed diagnosis of malignancy 4. At screening/ enrollment, meet the definition of sarcopenia according to the 2019 Asian Working Group for Sarcopenia 5. Generally good condition, ECOG performance status ≤ 2 6. Agree to provide peripheral blood, stool, and urine samples for biomarker analysis during the study Exclusion Criteria: 1. Presence of gastrointestinal obstruction preventing oral intake at screening/enrollment 2. Use of immunosuppressants at screening/enrollment 3. Life expectancy ≤ 3 months 4. Presence of malabsorption syndrome or any condition affecting gastrointestinal absorption, e.g., chronic diarrhea (watery stools; daily stool frequency ≥ 5 times) 5. Patients planning pregnancy, pregnant, or breastfeeding 6. Known allergy to any component of the investigational products 7. Presence of severe primary diseases of the heart, brain, lung, liver, kidney, endocrine, blood, nervous systems or other acute/chronic diseases that could significantly affect treatment and prognosis 8. Presence of other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or patients deemed unsuitable for the study by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm Malnutrition nutritional deficiency disease Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal cancers Nutritional deficiency Sarcopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    Hangzhou, Zhejiang, 310000, China

  • Hangzhou Institute of Medicine Chinese Academy of Sciences

    Hangzhou, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310003, China

  • The Second Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.